REG - Avacta Group PLC - Faridoxorubicin Phase 1b SGC data

AvactaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251217:nRSQ8417La&default-theme=true

RNS Number : 8417L  Avacta Group PLC  17 December 2025

 

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful
tumor shrinkage in patients with salivary gland cancers

 

Preliminary Phase 1b data is in line with Phase 1a data reported at the
European Society of Medical Oncology in September 2025

 

Combined disease control rate of 90% across both Phase 1a and Phase 1b
patients with confirmed partial and minor responses observed

 

LONDON and PHILADELPHIA - December 17, 2025 - Avacta Therapeutics (AIM: AVCT),
a clinical stage biopharmaceutical company developing pre|CISION(®), a
tumor-activated oncology delivery platform, today announced compelling new
data in patients with salivary gland cancer (SGC) enrolled in the ongoing
Phase 1b trial of faridoxorubicin (AVA6000). The data show confirmed partial
and minor responses, consistent with data previously reported from the Phase
1a part of the study.

 

Faridoxorubicin is the first peptide drug conjugate (PDC) in Avacta's
pipeline. It consists of doxorubicin conjugated with Avacta's proprietary
pre|CISION(®) peptide and is specifically cleaved (released) by fibroblast
activation protein-alpha (FAP), which is over-expressed in the tumor
microenvironment, enabling targeted release of the doxorubicin payload.

 

SGC accounts for 6-8% of head and neck cancers, with approximately 2,500 cases
diagnosed in the U.S. each year.(1) SGC is a disease that does not respond to
chemotherapy, has no standard therapy defined in the metastatic setting and a
five-year survival rate of approximately 42%(2) in advanced stage disease.

 

Avacta's recent data demonstrate continued robust and meaningful tumor
shrinkage in patients with SGCs and a combined disease control rate of 90%
across Phase 1a and Phase 1b patients.

 

Based on the preliminary favorable efficacy and safety data observed in the
Phase 1b cohort in this part of the trial, enrollment will continue in this
cohort with further data updates across the Phase 1a and Phase 1b cohorts
expected in 1H 2026.

 

Christina Coughlin MD, PhD, CEO of Avacta, commented:

 

"These data continue to reinforce our belief in the transformative potential
of our pre|CISION(®) peptide drug conjugates to expand the therapeutic index
and increase the efficacy of highly potent therapeutics and further
strengthens our confidence across our broader pipeline.

 

"SGC cancer is a devastating disease with no established standard of care
treatment options. The clinically meaningful tumor shrinkage and prolonged
progression free survival we have observed in the study highlight
faridoxorubicin's potential as an important new treatment option for patients
with SGC and other solid tumors. The Phase 1b data will mature as we continue
to collect the survival data in this cohort.

 

"Translational data collected from this population continue to demonstrate the
power of our pre|CISION(®) platform, with optimal payload release observed
even at the lowest levels of FAP expression. This supports a broad market
opportunity for all pre|CISION(®) medicines across our pipeline."

 

 

Faridoxorubicin (AVA6000) - Clinical data observations in SGC

These data demonstrate ongoing evidence of durable anti-tumor activity in
patients with SGC (both treatment-naïve and those who have failed earlier
lines of therapy), that is supported by ongoing RECIST(3) responses (both
partial and minor responses) and continued observation of a robust disease
control rate and strong progression-free survival (PFS) data. The trial
enrolled both a Phase 1a cohort (n=11) and Phase 1b cohort to date (n=19
evaluable for efficacy) for a total of 30 patients with SGC.

 

Of the 30 patients with SGC treated at the dose of 250 mg/m(2) and above and
evaluable for efficacy, nine  experienced clinically meaningful disease
shrinkage, including two confirmed partial responses (PR, >30% tumor
shrinkage) and seven minor responses (MR, >10% and <30% tumor shrinkage)
using RECISTv1.1 criteria. PFS in the Phase 1b cohort has not been reached
with a median follow up  exceeding 15 weeks at the data cutoff.

 

These data include the following:

·    Nineteen patients in the Phase 1b arm of the trial are evaluable for
efficacy. Safety findings (n=22) are in line with those data reported in the
Phase 1a cohort. Three patients enrolled were not evaluable for efficacy at
the data cutoff (2 patients not eligible and 1 patient not having reached an
initial follow up scan) but having received one dose of drug are considered
evaluable for safety

·    The baseline characteristics of the patients enrolled in the Phase 1b
are in line with the patients in Phase 1a.  In Phase 1b, the median number of
prior therapy regimens in the metastatic setting is 1 with a range of 0-2.
Seven patients in Phase 1b had not received prior systemic therapy

·    Among the total of 30 patients evaluable for efficacy treated at the
dose of 250 mg/m(2) and above in Phase 1a and 1b, 27 patients demonstrated
partial or minor responses or stable disease, resulting in a disease control
rate of 90% across the two arms in line with previously reported data

·    Clinically meaningful tumor shrinkage was observed with two patients
with confirmed partial responses and seven patients with confirmed minor
responses (across Phase 1a and 1b)

·    Median progression free survival in the cohort of 19 patients in the
Phase 1b has not been reached. Thirteen of 19 patients remain on therapy and
an additional two patients remain in PFS follow-up at the data cutoff

 

Although the Phase 1b data are early in the treatment course of most patients,
the emerging data are consistent with the previously reported Phase 1a
observations with no diminution of activity observed in SGC. Faridoxorubicin
continues to demonstrate the favorable safety profile and efficacy in SGC that
has characterized it since its initial clinical evaluation.

 

(1) Key Statistics in Salivary Gland Cancers (2025) | American Cancer Society.
Available at: www.cancer.org/cancer/types/salivary-gland-cancer.html
(http://www.cancer.org/cancer/types/salivary-gland-cancer.html)

(2) Survival rates for salivary gland cancer: Salivary gland survival (2025)
Salivary Gland Survival | American Cancer Society. Available at:
https://www.cancer.org/cancer/types/salivary-gland-cancer/detection-diagnosis-staging/survival-rates.html
(https://www.cancer.org/cancer/types/salivary-gland-cancer/detection-diagnosis-staging/survival-rates.html)

(3) Reduction in the sum of longest diameters (SLD) is used to measure
response per RECIST 1.1 with partial responses having at least a 30% reduction
and minor responses of between >10% and <30% reduction.

 

 

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer                via ICR Healthcare

 Peel Hunt (Nomad and Broker)                               www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden / Ben Harris

 Zeus (Joint Broker)                                        www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry / Dominic King

 ICR Healthcare                                             avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

                                                            renee@thrustsc.com (mailto:renee@thrustsc.com)

 Investor Contact

 Renee Leck

 THRUST Strategic Communications

 Media Contact                                              carly@thrustsc.com (mailto:carly@thrustsc.com)

 Carly Scaduto

 THRUST Strategic Communications

 

 

About Avacta - www.avacta.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.avacta.com%2F&data=05%7C02%7CChris.Coughlin%40avacta.com%7Ce5faa8dfbe3d49fc56f808dd35799958%7C64d2165ff9e04869bc73bfe4fc4fa9ab%7C0%7C0%7C638725518576703790%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=qWTC74zmTzjVQqwaFiKeiHUwMY5RUlsvb7C%2BkLRahGU%3D&reserved=0)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary payload delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent payloads in the tumor microenvironment
while sparing normal tissues.

 

Our innovative pipeline consists of pre|CISION(®) peptide drug conjugates
(PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific
release mechanism, providing unique benefits over traditional antibody drug
conjugates.

 

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAEAKFLXSFAA



            Copyright 2019 Regulatory News Service, all rights reserved